Form 8-K - Current report:
SEC Accession No. 0001213900-25-064774
Filing Date
2025-07-16
Accepted
2025-07-16 17:25:42
Documents
16
Period of Report
2025-07-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0249230-8k_nkgen.htm   iXBRL 8-K 36229
2 COMMON STOCK PURCHASE WARRANT, DATED JULY 14, 2025, BY AND BETWEEN NKGEN BIOTECH ea024923001ex4-1_nkgen.htm EX-4.1 133530
3 STOCK PURCHASE AGREEMENT, DATED JULY 14, 2025, BY AND BETWEEN NKGEN BIOTECH, INC ea024923001ex10-1_nkgen.htm EX-10.1 200413
4 PRESS RELEASE, DATED JULY 16, 2025 ea024923001ex99-1_nkgen.htm EX-99.1 14247
  Complete submission text file 0001213900-25-064774.txt   678646

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE nkgn-20250714.xsd EX-101.SCH 3887
6 XBRL DEFINITION FILE nkgn-20250714_def.xml EX-101.DEF 26782
7 XBRL LABEL FILE nkgn-20250714_lab.xml EX-101.LAB 37007
8 XBRL PRESENTATION FILE nkgn-20250714_pre.xml EX-101.PRE 25406
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0249230-8k_nkgen_htm.xml XML 5593
Mailing Address 3001 DAIMLER ST, SANTA ANA CA 92705
Business Address 3001 DAIMLER ST, SANTA ANA CA 92705 (949) 396-6830
NKGen Biotech, Inc. (Filer) CIK: 0001845459 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40427 | Film No.: 251128161
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)